Antiviral drug resistance testing in patients with chronic hepatitis B

Digestive Diseases and Sciences

Volumn 57, Issue 1, 2012, Pages 221-231

  Wong, Vincent Wai Sun ^a,b   Wong, Grace Lai Hung ^a,b   Tse, Chi Hang ^a,b   Yuen, Lilly K W ^c   Chan, Hoi Yun ^a,b   Locarnini, Stephen A ^c   Chan, Henry Lik Yuen ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Victorian Infectious Disease Research Laboratory   (Australia)

Author keywords

Adefovir dipivoxil; Entecavir; Lamivudine; Telbivudine; Tenofovir; Viral load

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; TELBIVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIAL SENSITIVITY TEST; MONOTHERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; VIRUS MUTANT; WILD TYPE;

ADENINE; ADULT; ANTIVIRAL AGENTS; DATA COLLECTION; DECISION MAKING; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84856758731     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1816-6     Document Type: Article

References (27)

1. HL Chan JJ Sung 2006 Hepatocellular carcinoma and hepatitis B virus Semin Liver Dis 26 153 161 16673293 10.1055/s-2006-939753 1:CAS:528: DC%2BD28Xltlegsr0%3D (Pubitemid 43668257)
2. CJ Chen HI Yang J Su, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 16391218 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D (Pubitemid 43042691)
3. VW Wong SL Chan F Mo, et al. 2010 Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers J Clin Oncol 28 1660 1665 20194845 10.1200/JCO.2009.26.2675 1:CAS:528:DC%2BC3cXmtVyhurg%3D
4. JJ Sung KK Tsoi VW Wong KC Li HL Chan 2008 Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment Pharmacol Ther 28 1067 1077 18657133 10.1111/j.1365-2036.2008.03816.x 1:STN:280:DC%2BD1cnpt12rtw%3D%3D
5. VW Wong GL Wong AM Chim, et al. 2009 Surrogate end points and long-term outcome in patients with chronic hepatitis B Clin Gastroenterol Hepatol 7 1113 1120 19500693 10.1016/j.cgh.2009.05.025
6. YF Liaw N Leung JH Kao, et al. 2008 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 19669255 10.1007/s12072-008-9080-3
7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-242.
8. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 661 662 19714720 10.1002/hep.23190
9. NW Leung CL Lai TT Chang, et al. 2001 Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 33 1527 1532 11391543 10.1053/jhep.2001.25084 1:CAS:528:DC%2BD3MXktlygtLc%3D (Pubitemid 32496991)
10. VW Wong GL Wong SW Tsang, et al. 2008 Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B Antivir Ther 13 571 579 18672536 (Pubitemid 352016720)
11. SJ Hadziyannis NC Tassopoulos EJ Heathcote, et al. 2006 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 1743 1751 17087951 10.1053/j.gastro.2006.09.020 1:CAS:528:DC%2BD2sXhtFyltLs%3D (Pubitemid 44958517)
12. AS Lok CL Lai N Leung, et al. 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714 1722 14724824 10.1053/j.gastro.2003.09.033 1:CAS:528:DC%2BD2cXhtVOrug%3D%3D (Pubitemid 37500436)
13. YF Liaw E Gane N Leung, et al. 2009 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 486 495 19027013 10.1053/j.gastro.2008.10.026 1:CAS:528:DC%2BD1MXislOhtLs%3D
14. YS Lee DJ Suh YS Lim, et al. 2006 Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy Hepatology 43 1385 1391 16729316 10.1002/hep.21189 1:CAS:528:DC%2BD28XmsF2msr8%3D (Pubitemid 43980117)
15. HL Chan AK Chui WY Lau, et al. 2002 Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation J Med Virol 68 182 187 12210406 10.1002/jmv.10185 1:CAS:528:DC%2BD38XntlaqtLg%3D
16. HL Chan SW Tsang CT Liew, et al. 2002 Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection Am J Gastroenterol 97 406 412 11866280 10.1111/j.1572-0241.2002.05478.x 1:CAS:528:DC%2BD38XitVKnurc%3D (Pubitemid 34160768)
17. A Ayres S Locarnini A Bartholomeusz 2004 HBV genotyping and analysis for unique mutations Methods Mol Med 95 125 149 14762302 1:CAS:528: DC%2BD2cXitFGktbs%3D
18. P Lampertico M Vigano E Manenti M Iavarone E Sablon M Colombo 2007 Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 1445 1451 17983801 10.1053/j.gastro.2007.08.079 1:CAS:528:DC%2BD2sXhsVGqtr%2FL (Pubitemid 350047463)
19. S Villet C Pichoud G Billioud, et al. 2008 Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure J Hepatol 48 747 755 18331765 10.1016/j.jhep.2008.01.027 1:CAS:528:DC%2BD1cXktVGrtbY%3D
20. N Warner S Locarnini 2008 The antiviral drug selected hepatitis B virus rtA181T/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound Hepatology 48 88 98 18537180 10.1002/hep.22295 1:CAS:528:DC%2BD1cXptFemtbY%3D (Pubitemid 351975534)
21. TT Chang RG Gish R de Man, et al. 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 16525137 10.1056/NEJMoa051285 1:CAS:528:DC%2BD28XitFWms7Y%3D (Pubitemid 43357804)
22. DJ Tenney RE Rose CJ Baldick, et al. 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 1503 1514 19280622 10.1002/hep.22841 1:CAS:528:DC%2BD1MXlslKmurw%3D
23. Y Karino J Toyota H Kumada, et al. 2010 Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B Hepatol Int 4 414 422 20305760 10.1007/s12072-009-9162-x
24. T Ide M Sata K Chayama, et al. 2010 Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy Hepatol Int 4 594 600 21063482 10.1007/s12072-010-9185-3
25. B Degertekin M Hussain J Tan K Oberhelman AS Lok 2009 Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance J Hepatol 50 42 48 19019484 10.1016/j.jhep.2008.08.020 1:CAS:528:DC%2BD1cXhsVCkt7%2FO
26. C Ding VW Wong KC Chow, et al. 2006 Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy Antivir Ther 11 1041 1049 17302374 1:CAS:528:DC%2BD2sXhtF2qt7g%3D (Pubitemid 44955180)
27. YY Lui KK Tsoi VW Wong, et al. 2010 Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy Antivir Ther 15 145 155 20386069 10.3851/IMP1496 1:CAS:528:DC%2BC3cXlvF2qs74%3D